Your shopping cart is empty!
PDF Preview
Clinical and Laboratory Standards Institute, 09/01/2021
Publisher: CLSI
File Format: PDF
$90.00$180.00
Published:01/09/2021
Pages:178
File Size:1 file , 9 MB
Note:This product is unavailable in Russia, Belarus
This guideline provides a framework for facilitating consistency in reporting genotypes and bacterial, viral, and fungal strain typing and will assist laboratories that perform these studies and the professionals applying the results. Its purpose is to present not only the technologies used but also the criteria to be considered for design, verification, validation, and determination of clinical utility of such testing. These technologies are now used in many different contexts, including: Clinical care settings Public health investigations, particularly of emerging infections Food and pharmaceutical industries Environmental analyses in the clinical setting Regulatory agencies This guideline is intended for manufacturers or laboratories that develop assays, laboratories that perform assays, clinicians who use the results to diagnose or manage patients, and agencies that regulate their use. This guideline: Is not intended for use by research laboratories Is not intended to provide manufacturing guidelines Does not discuss the development of standard reference materials for QC use It is recommended that this guideline be used in conjunction with CLSI documents MM03, MM06, MM09, MM12, MM13, MM14, MM17, MM18, and MM22.
Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine; Proposed Guideline
$147.00 $295.45
Assessment of Laboratory Tests When Proficiency Testing is Not Available; Approved Guideline--Second Edition, GP29A2E
$90.00 $180.00
One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline - Second Edition., H47-A2
Clinical Evaluation of Immunoassays; Approved Guideline--Second Edition, ILA21A2E
